Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/3292
Title: Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C
Authors: Gonçales Junior, Fernando Lopes
Vigani, Aline
Gonçales, Neiva
Barone, Antonio Alci
Araújo, Evaldo
Focaccia, Roberto
Oliveira, Umbeliana
Coelho, Henrique Sérgio Morais
Paixao, Jacqueline
Perez, Renata de Mello [UNIFESP]
Lobato, Cirley
Weirich, Judith
Rosa, Heitor
Borges, Andrelina
Vila, Ricardo
Corrêa-Giannella, Maria Lúcia
Ferraz, Maria Lucia Cardoso Gomes [UNIFESP]
Faculty of Medical Sciences of Campinas
São Paulo University School of Medicine
Emilio Ribas Institute
Federal University of Rio de Janeiro
Universidade Federal de São Paulo (UNIFESP)
Secretary of Health of Acre
Federal University of Goiás
Schering-Plough Brazil
São Paulo University Medical School Laboratory of Medical Investigations
Keywords: Hepatitis C
interferon alpha-2b
therapy
Issue Date: 1-Oct-2006
Publisher: Brazilian Society of Infectious Diseases
Citation: Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 10, n. 5, p. 311-316, 2006.
Abstract: Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (< 65 kg, 65-85 kg and > 85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression.
URI: http://repositorio.unifesp.br/handle/11600/3292
ISSN: 1413-8670
Other Identifiers: http://dx.doi.org/10.1590/S1413-86702006000500002
Appears in Collections:Em verificação - Geral

Files in This Item:
File Description SizeFormat 
S1413-86702006000500002.pdf63.34 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.